Database: Netherlands Cancer Registry (NKR) (The Netherlands)
Go back to The Netherlands page
Primary purpose: Record and monitor cancer statistics across the Netherlands to improve quality of care and ability to treat disease.
Sponsor, manager or home institution: Comprehensive Cancer Center of the Netherlands (IKNL).
Type of information: age, sex, place of residence, diagnosis, primary tumor localization, tumor histology, tumor staging, comorbidities, medical procedures, screening, hospital location, number of patients, number of medical staff, length of stay, number of visits, type of medical activity, number of deaths, causes of death, substance name, year, risk factors. Data dictionary - Netherlands Cancer Registry (NKR). Click here to learn more.
Available type of information: NKR Figures includes cancer incidence; diagnosis; sex; age; region; year; cancer prevalence; cancer mortality; cancer survival; relative survival; and tumor staging. Click here to learn more.
Also, there is a Cancer Atlas that informs of the incidence of cancer in each region of the Netherlands in the period of 2011–2020 and compares it to the Dutch average. This information can be selected by type of cancer, region, and gender. Click here to learn more.
Source of information: Hospitals' reports. Click here to learn more.
Data level: patient level.
Available data level: regional level and national level.
Number of Records: Contains information about all new cases of malignant neoplasms and some benign neoplasms (tumors of the central nervous system, borderline tumors of the ovary, and AL amyloidosis) in the Netherlands.
Date range: varies according to the diagnosis and the type of information. Click here to learn more.
Cancer Areas of Interest: C00-D48: All neoplasms. Click here to learn more.
Data access: partially publicly available. Publicly available data are the NKR Figures: Click here to access and the Cancer atlas: Click here to access. Instructions to request data for restricted content Click here to learn more.
Contact information: Click here to learn more.